Literature DB >> 27240275

Recent advances in the discovery of heparanase inhibitors as anti-cancer agents.

Li Jia1, Shutao Ma2.   

Abstract

Heparanase, an only endo-β-d-glucuronidase capable of cleaving heparan sulfate (HS) side chains at specific sites, contributes to remodeling of the extracellular matrix (ECM) and releasing of HS-linked growth factors, cytokines and signaling proteins. In addition, heparanase also plays an indispensable role in tumor angiogenesis, invasion and metastasis, indicating that it is a promising target for the development of antitumor drugs. Recent progress leads to three classes of heparanase inhibitors, including active analogs of endogenous substance, synthetic small molecule compounds and natural products. In this review, following an outline on the heparanase structure and function, an overview of the advancement of heparanase inhibitors as novel and potent anti-cancer agents will be given, especially introducing various existing heparanase inhibitors, as well as their inhibitory activities and mechanisms of action.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Anti-Cancer agents; Heparan sulfate; Heparanase; Inhibitors

Mesh:

Substances:

Year:  2016        PMID: 27240275     DOI: 10.1016/j.ejmech.2016.05.052

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  10 in total

1.  CTC clusters induced by heparanase enhance breast cancer metastasis.

Authors:  Rong-Rui Wei; Dan-Ni Sun; Hong Yang; Juan Yan; Xiong Zhang; Xing-Ling Zheng; Xu-Hong Fu; Mei-Yu Geng; Xun Huang; Jian Ding
Journal:  Acta Pharmacol Sin       Date:  2018-02-08       Impact factor: 6.150

Review 2.  Elevated heparanase expression is associated with poor prognosis in breast cancer: a study based on systematic review and TCGA data.

Authors:  Xu Sun; Ganlin Zhang; Jiayun Nian; Mingwei Yu; Shijian Chen; Yi Zhang; Guowang Yang; Lin Yang; Peiyu Cheng; Chen Yan; Yunfei Ma; Hui Meng; Xiaomin Wang; Jin-Ping Li
Journal:  Oncotarget       Date:  2017-06-27

Review 3.  Heparan Sulfate Mimetics in Cancer Therapy: The Challenge to Define Structural Determinants and the Relevance of Targets for Optimal Activity.

Authors:  Cinzia Lanzi; Giuliana Cassinelli
Journal:  Molecules       Date:  2018-11-08       Impact factor: 4.411

Review 4.  Heparin Binding Proteins as Therapeutic Target: An Historical Account and Current Trends.

Authors:  Giancarlo Ghiselli
Journal:  Medicines (Basel)       Date:  2019-07-29

Review 5.  Heparanase and the hallmarks of cancer.

Authors:  Krishnath M Jayatilleke; Mark D Hulett
Journal:  J Transl Med       Date:  2020-11-30       Impact factor: 5.531

6.  Computational design and experimental characterisation of a stable human heparanase variant.

Authors:  Cassidy Whitefield; Nansook Hong; Joshua A Mitchell; Colin J Jackson
Journal:  RSC Chem Biol       Date:  2022-02-15

Review 7.  A narrative review of circulating tumor cells clusters: A key morphology of cancer cells in circulation promote hematogenous metastasis.

Authors:  Qiong Chen; Jueyao Zou; Yong He; Yanhong Pan; Gejun Yang; Han Zhao; Ying Huang; Yang Zhao; Aiyun Wang; Wenxing Chen; Yin Lu
Journal:  Front Oncol       Date:  2022-08-18       Impact factor: 5.738

8.  A Concise Synthesis of a BODIPY-Labeled Tetrasaccharide Related to the Antitumor PI-88.

Authors:  Juan Ventura; Clara Uriel; Ana M Gomez; Edurne Avellanal-Zaballa; Jorge Bañuelos; Inmaculada García-Moreno; Jose Cristobal Lopez
Journal:  Molecules       Date:  2021-05-14       Impact factor: 4.411

Review 9.  The Challenge of Modulating Heparan Sulfate Turnover by Multitarget Heparin Derivatives.

Authors:  Noemi Veraldi; Nawel Zouggari; Ariane de Agostini
Journal:  Molecules       Date:  2020-01-17       Impact factor: 4.411

Review 10.  The Glycocalyx and Its Role in Vascular Physiology and Vascular Related Diseases.

Authors:  Sheldon Weinbaum; Limary M Cancel; Bingmei M Fu; John M Tarbell
Journal:  Cardiovasc Eng Technol       Date:  2020-09-21       Impact factor: 2.495

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.